Literature DB >> 18474242

Glutamate-induced glioma cell proliferation is prevented by functional expression of the glutamate transporter GLT-1.

Nicolas Vanhoutte1, Emmanuel Hermans.   

Abstract

A tetracycline-dependent inducible system was used to achieve controlled expression of the glutamate transporter 1 (GLT-1) in C6 glioma cells. Non-induced cells show modest glutamate uptake and, in the presence of L-cystine, these cells tend to release substantial amounts of glutamate. Overnight exposure to doxycycline increased D-[3H]-aspartate uptake, reaching similar capacity as observed in cultured astrocytes. Efficient clearance of exogenously applied glutamate was evidenced in these cells, even in the presence of l-cystine. The addition of glutamate (100 microM) to the medium of non-induced cells significantly increased their proliferation rate, an effect that was blocked when the expression of GLT-1 was induced. This suggests that impaired glutamate uptake capacity in glioma cells indirectly contributes to their proliferation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474242     DOI: 10.1016/j.febslet.2008.04.053

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

Review 1.  Unique biology of gliomas: challenges and opportunities.

Authors:  Stacey Watkins; Harald Sontheimer
Journal:  Trends Neurosci       Date:  2012-06-08       Impact factor: 13.837

2.  Ketamine suppresses the proliferation of rat C6 glioma cells.

Authors:  Hidetomo Niwa; Ken-Ichi Furukawa; Kazuhiko Seya; Kazuyoshi Hirota
Journal:  Oncol Lett       Date:  2017-08-24       Impact factor: 2.967

3.  Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas.

Authors:  Fabio M Iwamoto; Teri N Kreisl; Lyndon Kim; J Paul Duic; John A Butman; Paul S Albert; Howard A Fine
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

4.  Glutamine synthetase gene expression and glutamate transporters in C6-glioma cells.

Authors:  Zafeer Baber; Nasrin Haghighat
Journal:  Metab Brain Dis       Date:  2010-11-25       Impact factor: 3.584

5.  AMPK Modulates the Metabolic Adaptation of C6 Glioma Cells in Glucose-Deprived Conditions without Affecting Glutamate Transport.

Authors:  Inês Belo do Nascimento; Marie Verfaillie; Gamze Ates; Pauline Beckers; Virginie Joris; Nathalie Desmet; Ann Massie; Emmanuel Hermans
Journal:  Cells       Date:  2022-05-31       Impact factor: 7.666

Review 6.  Glutamate transporters in the biology of malignant gliomas.

Authors:  Stephanie M Robert; Harald Sontheimer
Journal:  Cell Mol Life Sci       Date:  2013-11-27       Impact factor: 9.261

7.  Mitochondrial enzyme GLUD2 plays a critical role in glioblastoma progression.

Authors:  Sara Franceschi; Debora Corsinovi; Francesca Lessi; Elena Tantillo; Paolo Aretini; Michele Menicagli; Claudia Scopelliti; Prospero Civita; Francesco Pasqualetti; Antonio G Naccarato; Michela Ori; Chiara M Mazzanti
Journal:  EBioMedicine       Date:  2018-10-09       Impact factor: 8.143

8.  D-Aspartate treatment attenuates myelin damage and stimulates myelin repair.

Authors:  Valeria de Rosa; Agnese Secondo; Anna Pannaccione; Roselia Ciccone; Luigi Formisano; Natascia Guida; Roberta Crispino; Annalisa Fico; Roman Polishchuk; Antimo D'Aniello; Lucio Annunziato; Francesca Boscia
Journal:  EMBO Mol Med       Date:  2019-01       Impact factor: 12.137

9.  Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment.

Authors:  Dannis G van Vuurden; Maryam Yazdani; Ingeborg Bosma; Aart J F Broekhuizen; Tjeerd J Postma; Jan J Heimans; Paul van der Valk; Eleonora Aronica; Bakhos A Tannous; Thomas Würdinger; Gertjan J L Kaspers; Jacqueline Cloos
Journal:  PLoS One       Date:  2009-06-18       Impact factor: 3.240

10.  The role of metabotropic glutamate receptor 5 on the stromal cell-derived factor-1/CXCR4 system in oral cancer.

Authors:  Nobuyuki Kuribayashi; Daisuke Uchida; Makoto Kinouchi; Natsumi Takamaru; Tetsuya Tamatani; Hirokazu Nagai; Youji Miyamoto
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.